Ii-Key/HER2/neu cancer vaccine: Phase I data

A Phase I trial in 23 prostate cancer patients who received a booster vaccination with AE37 6 months post-primary vaccination showed that 0% of intermediate- (n=9) and high-risk (n=8) patients as dete...